Empasiprubar (ARGX-117) is a humanized inhibitory monoclonal antibody that specifically targets complement component C2. By binding to the Sushi-2 domain of C2, Empasiprubar effectively prevents the formation of C3 convertase, thereby inhibiting the activation of both the classical and lectin complement pathways upstream of C3. This inhibition is critical in mitigating the effects of complement-mediated autoimmune disorders, such as autoimmune hemolytic anemia, and in preventing antibody-mediated rejection in organ transplantation. Additionally, Empasiprubar has demonstrated potential in preventing neuroglial and lymphoconjunctival injuries in GM1 antibody-mediated mouse models, suggesting further applications in neuroinflammatory conditions. This antibody offers a promising therapeutic approach by targeting a key point in the complement activation cascade, providing broad utility in research focused on immune regulation and complement system-mediated diseases.
Empasiprubar (ARGX-117) is a humanized inhibitory monoclonal antibody that specifically targets complement component C2. By binding to the Sushi-2 domain of C2, Empasiprubar effectively prevents the formation of C3 convertase, thereby inhibiting the activation of both the classical and lectin complement pathways upstream of C3. This inhibition is critical in mitigating the effects of complement-mediated autoimmune disorders, such as autoimmune hemolytic anemia, and in preventing antibody-mediated rejection in organ transplantation. Additionally, Empasiprubar has demonstrated potential in preventing neuroglial and lymphoconjunctival injuries in GM1 antibody-mediated mouse models, suggesting further applications in neuroinflammatory conditions. This antibody offers a promising therapeutic approach by targeting a key point in the complement activation cascade, providing broad utility in research focused on immune regulation and complement system-mediated diseases.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
Please check COA/MSDS for correct molecular weight.
Calculate the dilution required to prepare a stock solution.This equation is commonly abbreviated as: C1V1 = C2V2
Frequently Asked Questions
What are Biosimilar Antibodies?
Biosimilar antibodies are research-grade recombinant antibodies designed to closely resemble approved therapeutic antibodies in terms of amino acid sequence, structural characteristics, and biological activity. These antibodies are generated using recombinant expression technologies and retain the same variable regions as their corresponding reference therapeutics, thereby preserving target specificity and binding affinity. Owing to these properties, biosimilar antibodies serve as reliable and cost-effective research reagents for applications in drug discovery, pharmacological studies, and basic biomedical research.
Research-grade biosimilar antibodies have been successfully expressed and functionally validated against a wide range of widely studied targets. These antibodies can be directly utilized as positive control reagents in drug discovery programs, as well as reference tools for rapid verification of the biological functions of target proteins in biochemical and cellular assays.
